Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide

Amanda Valliant, R Michael Hofmann Division of Nephrology, University of Wisconsin, Madison, WI, USA Abstract: Anemia in chronic kidney disease is a prevalent and expensive problem in the United States, and it is well documented that anemia worsens as glomerular filtration rates decline. The complic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Valliant A, Hofmann RM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/74f04593918841b5b15234e020eb857f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:74f04593918841b5b15234e020eb857f
record_format	dspace
spelling	oai:doaj.org-article:74f04593918841b5b15234e020eb857f2021-12-02T01:08:06ZManaging dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide1176-91141178-2013https://doaj.org/article/74f04593918841b5b15234e020eb857f2013-08-01T00:00:00Zhttp://www.dovepress.com/managing-dialysis-patients-who-develop-anemia-caused-by-chronic-kidney-a14162https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Amanda Valliant, R Michael Hofmann Division of Nephrology, University of Wisconsin, Madison, WI, USA Abstract: Anemia in chronic kidney disease is a prevalent and expensive problem in the United States, and it is well documented that anemia worsens as glomerular filtration rates decline. The complications of severe anemia in this patient population contribute significantly to their overall morbidity with increased cardiovascular complications, decreased quality of life, and increased dependence on transfusions to maintain adequate hemoglobin levels. Erythropoietin-stimulating agents (ESAs) have revolutionized the treatment of anemia in this population, but there has been a great deal of controversy surrounding the quest for the ideal hemoglobin target. In addition, there are economic and practice management implications where anemia treatment is concerned, with ongoing refinement of Centers for Medicare and Medicaid Services-bundled payments. One of the newest additions to the arsenal used to fight anemia in end-stage renal disease patients is peginesatide (Omontys), a synthetic, PEGylated, peptide-based ESA that acts by stimulating the erythropoietin receptor. The role of peginesatide in the future treatment of anemia in chronic kidney disease remains uncertain, with new safety concerns being brought to attention as it emerges on the market, prompting a national recall. Keywords: anemia, chronic kidney disease, peginesatideValliant AHofmann RMDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss default, Pp 3297-3307 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Valliant A Hofmann RM Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
description	Amanda Valliant, R Michael Hofmann Division of Nephrology, University of Wisconsin, Madison, WI, USA Abstract: Anemia in chronic kidney disease is a prevalent and expensive problem in the United States, and it is well documented that anemia worsens as glomerular filtration rates decline. The complications of severe anemia in this patient population contribute significantly to their overall morbidity with increased cardiovascular complications, decreased quality of life, and increased dependence on transfusions to maintain adequate hemoglobin levels. Erythropoietin-stimulating agents (ESAs) have revolutionized the treatment of anemia in this population, but there has been a great deal of controversy surrounding the quest for the ideal hemoglobin target. In addition, there are economic and practice management implications where anemia treatment is concerned, with ongoing refinement of Centers for Medicare and Medicaid Services-bundled payments. One of the newest additions to the arsenal used to fight anemia in end-stage renal disease patients is peginesatide (Omontys), a synthetic, PEGylated, peptide-based ESA that acts by stimulating the erythropoietin receptor. The role of peginesatide in the future treatment of anemia in chronic kidney disease remains uncertain, with new safety concerns being brought to attention as it emerges on the market, prompting a national recall. Keywords: anemia, chronic kidney disease, peginesatide
format	article
author	Valliant A Hofmann RM
author_facet	Valliant A Hofmann RM
author_sort	Valliant A
title	Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
title_short	Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
title_full	Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
title_fullStr	Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
title_full_unstemmed	Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
title_sort	managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/74f04593918841b5b15234e020eb857f
work_keys_str_mv	AT vallianta managingdialysispatientswhodevelopanemiacausedbychronickidneydiseasefocusonpeginesatide AT hofmannrm managingdialysispatientswhodevelopanemiacausedbychronickidneydiseasefocusonpeginesatide
_version_	1718403264214466560

Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide

Ejemplares similares